| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.6 |